How much does venetoclax/venetoclax cost per month?

Venetoclax/Venetoclax is a targeted drug used to treat chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Its price varies depending on multiple factors, such as purchasing channels, drug specifications, and medical insurance reimbursement policies. In China, the original drug of venetoclax is already on the market. Common specifications include 10mg*14 tablets, 50mg*7 tablets, 100mg*14 tablets and 100mg*4 tablets*7 tablets. Depending on the specifications and dosage, the price usually ranges from RMB 1,000 to RMB 4,000.

For patients with chronic lymphocytic leukemia, the starting dose of venetoclax is 20 mg daily and is gradually increased to 400 mg daily over five weeks. After reaching a stable dose, patients need to continue taking the dose of 400 mg in order to fully exert the effect of the drug. Although there are different brands and manufacturers on the market, the active ingredients of Venekra are the same, the main differences are the price and production process.

In overseas markets, the price of Venekra also varies. For example, in the Turkish market, the price of 112 tablets of 100mg Venekra can reach more than 10,000 yuan. This price is greatly affected by exchange rate fluctuations and may change at the time of actual purchase. In addition, there are also some generic drug options on the market. For example, the generic drug in Bangladesh has a specification of 100 mg and 120 tablets, and its price is about more than 4,000 yuan. Although generic drugs are more affordable, patients still need to pay attention to the quality and source of the drugs when choosing them to ensure efficacy and safety.

Overall, the monthly cost of venetoclax varies depending on the patient's specific treatment plan and the price of the drug chosen. Calculated based on a daily dose of 400 mg, the monthly drug cost may range from several thousand to ten thousand yuan. Especially in the absence of medical insurance reimbursement, patients need to comprehensively consider their own financial situation and treatment needs to make a reasonable choice.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto